Clinical Trial Update: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 study of INCB050465 in combination with ruxolitinib for myelofibrosis. The trial was terminated and results were posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• INCB050465
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: MPN (Myeloproliferative Neoplasms) | Phase 2 | Status: TERMINATED | Results posted: 2024-05-01